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A bs tr ac t
Background
Patients with systolic heart failure and anemia have worse symptoms, functional 
capacity, and outcomes than those without anemia. We evaluated the effects of dar be­
po e tin alfa on clinical outcomes in patients with systolic heart failure and anemia.
Methods
In this randomized, double­blind trial, we assigned 2278 patients with systolic heart 
failure and mild­to­moderate anemia (hemoglobin level, 9.0 to 12.0 g per deciliter) 
to receive either dar be po e tin alfa (to achieve a hemoglobin target of 13 g per deci­
liter) or placebo. The primary outcome was a composite of death from any cause or 
hospitalization for worsening heart failure.
Results
The primary outcome occurred in 576 of 1136 patients (50.7%) in the dar be po e tin 
alfa group and 565 of 1142 patients (49.5%) in the placebo group (hazard ratio in the 
dar be po e tin alfa group, 1.01; 95% confidence interval, 0.90 to 1.13; P = 0.87). There 
was no significant between­group difference in any of the secondary outcomes. The 
neutral effect of dar be po e tin alfa was consistent across all prespecified subgroups. 
Fatal or nonfatal stroke occurred in 42 patients (3.7%) in the dar be po e tin alfa group 
and 31 patients (2.7%) in the placebo group (P = 0.23). Thromboembolic adverse 
events were reported in 153 patients (13.5%) in the dar be po e tin alfa group and 114 
patients (10.0%) in the placebo group (P = 0.01). Cancer­related adverse events were 
similar in the two study groups.
Conclusions
Treatment with dar be po e tin alfa did not improve clinical outcomes in patients with 
systolic heart failure and mild­to­moderate anemia. Our findings do not support the 
use of dar be po e tin alfa in these patients. (Funded by Amgen; RED­HF ClinicalTrials 
.gov number, NCT00358215.)
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A nemia is common in patients with heart failure, and patients with both heart failure and anemia have a lower function­
al capacity, worse quality of life, and higher rates 
of hospitalization and death1-3 than those without 
anemia.4,5 The cause of anemia in patients with 
heart failure is often unknown but may be related 
to an absolute or relative deficiency of, or resis­
tance to, erythropoietin. Anemia in such patients 
is associated with impaired renal function, inflam­
mation, and use of renin–angiotensin system 
blockers.6,7
Small studies have suggested that increasing 
the hemoglobin level with the use of an erythro­
poiesis­stimulating agent (ESA) may improve func­
tional capacity8-13 and reduce hospitalization in 
patients with heart failure and anemia, but the 
evidence is not robust.14,15 Furthermore, ESAs 
have not improved cardiovascular outcomes in 
patients with chronic kidney disease who had 
anemia, with or without diabetes, and treatment 
aimed at a high hemoglobin target has increased 
the risk of atherothrombotic events.16-18 The aim 
of our study, the Reduction of Events by Dar be­
po e tin Alfa in Heart Failure (RED­HF) trial, was 
to determine whether treatment with dar be po e­
tin alfa improves clinical outcomes in patients 
with chronic systolic heart failure and anemia 
that is not due to iron deficiency.
Me thods
Study Design and Oversight
The study design has been reported previously.19 
The executive committee and steering committee 
designed and oversaw the conduct of the trial, 
including data analysis, in collaboration with rep­
resentatives of the sponsor (Amgen). The ethics 
committee at each study center approved the trial 
design. Data were collected and managed by the 
sponsor. The University of Wisconsin Statistical 
Data Analysis Center (SDAC) prepared unblinded 
reports for the independent data and safety mon­
itoring committee, which met approximately ev­
ery 3 months to oversee patient safety. The trial 
results were analyzed by the sponsor according 
to a predefined statistical analysis plan, and the 
analyses were replicated by SDAC. The manu­
script was prepared by an academic publications 
committee, whose members had unrestricted ac­
cess to the data, and was subsequently revised by 
all the authors. All the authors participated in 
the decision to submit the manuscript for publi­
cation and assume responsibility for the accuracy 
and completeness of the data, as well as for the 
fidelity of this report to the trial protocol, which 
is available with the full text of this article at 
NEJM.org.
Study Patients
Patients were eligible for the study if they had 
New York Heart Association (NYHA) functional 
class II, III, or IV heart failure; a left ventricular 
ejection fraction of 40% or less; and a hemoglobin 
level of 9.0 to 12.0 g per deciliter and if they were 
receiving guideline­recommended heart­failure 
therapy. Major exclusion criteria were a transferrin 
saturation of less than 15%, evidence of bleeding 
or other correctable causes of anemia, a serum 
creatinine level of more than 3 mg per deciliter 
(265 μmol per liter), and a blood pressure of more 
than 160/100 mm Hg. All patients provided writ­
ten informed consent.
Study Procedures
Patients were randomly assigned in a 1:1 ratio to 
receive either dar be po e tin alfa or placebo. Ran­
domization was stratified according to region and 
whether patients were receiving therapy with an 
implantable cardioverter–defibrillator, cardiac re­
synchronization, or both.
Doses of dar be po e tin alfa and placebo were 
identical in appearance and packaging. The study 
drug was administered subcutaneously, with dos­
es adjusted according to hemoglobin level, which 
was measured in a blinded fashion. Patients in 
the dar be po e tin alfa group received a starting 
dose of 0.75 μg per kilogram of body weight once 
every 2 weeks until a hemoglobin level of 13.0 g 
per deciliter was reached on two consecutive vis­
its. Thereafter, patients received monthly injec­
tions, according to an algorithm19 that was de­
signed to maintain a hemoglobin level of 13.0 g 
per deciliter (but not exceeding 14.5 g per deci­
liter) (Table S1 in the Supplementary Appendix, 
available at NEJM.org). Patients in the placebo 
group received dose adjustments to mimic those 
in the dar be po e tin alfa group. Dose assignments 
in the two groups were performed by an interac­
tive voice­response system.
Blood iron indexes were assessed every 3 months 
during the trial. If the transferrin saturation fell to 
less than 20% at any time during the study, oral 
(and, if necessary, intravenous) iron was admin­
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istered as tolerated, according to a specified al­
gorithm (for details, see the Supplementary Ap­
pendix). Use of supplemental iron was recorded.
Study Outcomes
The primary outcome was a composite of death 
from any cause or first hospitalization for wors­
ening heart failure. The prespecified adjudicated 
secondary outcomes were death from any cause 
and the composite of death from cardiovascular 
causes or first hospitalization for worsening heart 
failure. Additional secondary outcomes were the 
change from baseline to 6 months in the Overall 
Summary Score and Symptom Frequency Score on 
the Kansas City Cardiomyopathy Questionnaire 
(KCCQ).20 The KCCQ scores range from 0 to 100, 
with higher scores indicating better quality of 
life and fewer symptoms and a change of 5 points 
considered to be clinically meaningful.21 Clinical 
events were adjudicated according to prespeci­
fied definitions (Table S2 in the Supplementary 
Appendix) by members of an independent com­
mittee whose members were unaware of study­
group assignments and hemoglobin levels.
Statistical Analysis
We determined that the primary outcome would 
need to occur in approximately 1150 patients in 
order to detect a between­group difference of 20 
percentage points (assuming an annualized event 
rate of 25% in the placebo group) with a power of 
80% after adjustment for the attenuation of treat­
ment effect. The overall type I error was controlled 
at a significance level of 0.05. The protocol origi­
nally assumed that approximately 2600 patients 
would be enrolled for the accrual of 1150 events. 
However, because enrollment took longer than 
anticipated, 1150 events were expected to accrue 
before the enrollment target was reached, and 
recruitment was stopped after 2278 patients had 
been randomly assigned to a study group.
All patients who underwent randomization 
were included in analyses of the primary and 
secondary outcomes. We used the Kaplan–Meier 
approach and a two­sided stratified log­rank test 
to perform time­to­event analyses. Hazard ratios 
and 95% confidence intervals were estimated 
with the use of stratified Cox proportional­hazards 
models. We performed a secondary analysis of 
the primary outcome using a Cox proportional­
hazards model that was adjusted for the stratifi­
cation variables, as well as for baseline age, sex, 
NYHA functional class, hospitalization for heart 
failure within 6 months before randomization 
(yes vs. no), diabetes (yes vs. no), log serum cre­
atinine level, ejection fraction, cause of heart fail­
ure (ischemic vs. nonischemic), body­mass index, 
left bundle­branch block (yes vs. no), history of 
atrial fibrillation or flutter (yes vs. no), and sys­
tolic blood pressure.
The consistency of the treatment effect was as­
sessed in an as­treated analysis, which included 
only the outcomes that occurred on or before the 
date of the last dose of the study drug plus 30 days. 
The primary outcome was also analyzed according 
to age; sex; race or ethnic group; region; treatment 
with an implantable cardioverter–defibrillator, 
cardiac resynchronization therapy, or both; and 
estimated glomerular filtration rate (GFR). The 
patient­reported secondary outcomes were ana­
lyzed with the use of a mixed­effects model after 
adjustment for the stratification variables and the 
baseline KCCQ score. We used the Medical Diction-
ary for Regulatory Activities, version 15.1, to identify 
all adverse events of interest. Query search strat­
egies were specified in the statistical analysis plan. 
All statistical analyses were performed with the 
use of SAS software, version 9.2. (Additional 
information on statistical methods is provided 
in the Supplementary Appendix.)
R esult s
Patients
From June 13, 2006, to May 4, 2012, a total of 2278 
patients underwent randomization at 453 sites in 
33 countries. Of these patients, 1136 were as­
signed to the dar be po e tin alfa group and 1142 to 
the placebo group (Fig. S1 in the Supplementary 
Appendix). The study groups were balanced with 
respect to baseline characteristics22 (Table 1, and 
Table S3 in the Supplementary Appendix). The me­
dian age was 72.0 years; 41% of the patients were 
women, 65% had NYHA class III or IV disease, 
the median left ventricular ejection fraction was 
31%, and the median estimated GFR was 45.7 ml 
per minute per 1.73 m2 of body­surface area.
Study-Drug Administration and Follow-up
Five patients (3 in the dar be po e tin alfa group and 
2 in the placebo group) did not receive any doses 
of the study drug and were not included in the 
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Table 1. Characteristics of the Patients at Baseline.*
Characteristic
Dar be po e tin Alfa 
(N = 1136)
Placebo 
(N = 1142)
Median age (interquartile range) — yr 72.0 (63.0–78.0) 71.0 (63.0–78.0)
Female sex (%) 40.3 42.6
Race (%)†
White 68.8 67.3
Black 7.8 9.9
Other 23.4 22.8
Median body-mass index (interquartile range)‡ 26.1 (23.3–30.0) 26.3 (23.4–30.2)
New York Heart Association class (%)
II 32.6 36.9
III or IV 67.4 63.0
Median left ventricular ejection fraction (interquartile 
range) — %
31.0 (25.0–35.0) 30.0 (25.0–35.0)
Median duration of heart failure (interquartile range) — yr 3.8 (1.3–7.5) 3.5 (1.2–7.7)
Ischemic heart failure (%) 73.2 72.6
Medical history (%)
Hypertension 73.0 74.1
Diabetes 46.3 46.3
Atrial fibrillation or flutter 33.3 32.3
Stroke (hemorrhagic or ischemic) 7.7 8.0
Hospitalization for heart failure within past 6 mo 35.4 38.4
Cancer§ 8.2 6.8
Medication (%)
ACE inhibitor or ARB 87.9 89.9
Beta-blocker 85.4 84.7
Diuretic 90.5 92.5
Mineralocorticoid-receptor antagonist 43.6 45.8
Median blood pressure (interquartile range) — mm Hg
Systolic 120.0 (109.0–133.0) 120.0 (108.0–130.0)
Diastolic 70.0 (60.0–80.0) 70.0 (60.0–78.0)
Median heart rate (interquartile range) — beats/min 72.0 (64.0–80.0) 71.0 (64.0 –80.0)
Median laboratory values (interquartile range)
Creatinine — mg/dl 1.40 (1.10–1.80) 1.40 (1.10 –1.80)
Estimated glomerular filtration rate — ml/min/1.73 m2 45.6 (34.0–61.3) 45.8 (34.1–61.6)
Hemoglobin — g/dl 11.15 (10.55–11.60) 11.20 (10.65–11.65)
Transferrin saturation — % 24.0 (19.0–31.0) 24.0 (19.0–31.0)
* There were no significant differences between the two groups except for New York Heart Association class (P<0.05).  
P values were not adjusted for multiple comparisons. To convert the values for creatinine to micromoles per liter, mul-
tiply by 88.4. ACE denotes angiotensin-converting enzyme, and ARB angiotensin-receptor blocker.
† Race was self-reported.
‡ The body-mass index is the weight in kilograms divided by the square of the height in meters.
§ Not included in this category were patients with a history of basal-cell carcinoma, squamous-cell carcinoma, or cervical 
intraepithelial neoplasia.
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safety analysis. The study drug was discontinued 
for reasons other than death in 368 patients 
(32.4%) in the dar be po e tin alfa group and 412 
patients (36.1%) in the placebo group (Table S4 
in the Supplementary Appendix).
The study was terminated on September 1, 
2012, with a median follow­up of 28 months. 
Vital status at study termination was unknown 
for 13 patients (1.1%) in the dar be po e tin alfa 
group and 21 (1.8%) in the placebo group be­
cause of loss to follow­up or withdrawal of con­
sent (Fig. S1 in the Supplementary Appendix). If 
contact could not be made at the time of study 
termination, data were censored in the analysis 
at the time of the last contact.
Hemoglobin Values
The median hemoglobin level at baseline was 
11.2 g per deciliter in the two study groups (Ta­
ble 1). On the basis of the area under the curve 
(AUC), the median attained hemoglobin level over 
time was 13.0 g per deciliter (interquartile range, 
12.4 to 13.4) in the dar be po e tin alfa group and 
11.5 g per deciliter (interquartile range, 10.7 to 
12.2) in the placebo group (P<0.001) (Fig. 1).
The between­group difference in the hemo­
globin level was significant by 1 month after 
randomization and remained so throughout the 
study. In the 1122 patients in each study group 
who received a study drug and provided a post­
baseline blood sample, the hemoglobin value was 
13.0 g per deciliter or more on three consecutive 
occasions in 807 patients (71.9%) in the dar be po­
e tin alfa group and 241 (21.5%) in the placebo 
group (P<0.001). The median monthly dose in the 
dar be po e tin alfa group was 167 μg (interquartile 
range, 105 to 286).
Anemia Treatments in Addition  
to the Study Drug
A total of 40 patients (3.5%) in the dar be po e tin 
alfa group and 77 (6.7%) in the placebo group 
received at least one dose of a nonstudy ESA 
(P<0.001). There was no significant difference in 
the proportion of patients who received iron at 
least once during the study (intravenous iron: 
4.9% in the dar be po e tin alfa group and 5.6% in 
the placebo group, P = 0.47; oral iron: 72.3% in the 
dar be po e tin alfa group and 73.5% in the placebo 
group, P = 0.52). Among patients who received a 
study drug, one or more blood transfusions were 
performed in 123 patients (10.9%) in the dar be­
po e tin alfa group and in 188 (16.5%) in the pla­
cebo group (P<0.001).
Study Outcomes
The primary composite outcome of death from 
any cause or first hospitalization for worsening 
heart failure occurred in 576 patients (50.7%) in 
the dar be po e tin alfa group and 565 (49.5%) in the 
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Figure 1. Monthly Hemoglobin Levels through 60 Months According to Study Group.
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placebo group (hazard ratio in the dar be po e tin 
alfa group, 1.01; 95% confidence interval [CI], 
0.90 to 1.13; P = 0.87) (Table 2 and Fig. 2A). The 
result of the analysis adjusted for baseline char­
acteristics was similar (adjusted hazard ratio, 1.01; 
95% CI, 0.90 to 1.13; P = 0.88), as was the result 
of the as­treated analysis (hazard ratio, 0.98; 95% 
CI, 0.86 to 1.13; P = 0.82). The result for the pri­
mary outcome was consistent across all sub­
groups examined (Fig. S2 in the Supplementary 
Appendix).
There were 474 deaths (41.7%) in the dar be­
po e tin alfa group and 458 (40.1%) in the placebo 
group (hazard ratio, 1.04; 95% CI, 0.92 to 1.19; 
P = 0.51) (Table 2 and Fig. 2B), corresponding to 
overall annualized mortality rates of 14.4% and 
13.8%, respectively. The number of patients who 
died from cardiovascular causes or had a first 
hospitalization for worsening heart failure was 
similar in the two study groups, as was the 
number of patients for each of the components 
of this composite outcome (Table 2 and Fig. 2). 
The total numbers of hospitalizations for heart 
failure (including second and subsequent hospi­
talizations) were 572 in the dar be po e tin alfa 
group and 695 in the placebo group (P = 0.06 
from a negative binomial model).
Fatal or nonfatal adjudicated stroke occurred 
in 42 patients (3.7%) in the dar be po e tin alfa group 
and 31 (2.7%) in the placebo group (hazard ratio, 
1.33; 95% CI, 0.83 to 2.12; P = 0.23). All other 
prespecified adjudicated outcomes are summa­
rized in Table 2.
The least­squares mean changes from baseline 
to month 6 in the Overall Summary Score of the 
KCCQ were 6.68 points (95% CI, 5.35 to 8.01) in 
the dar be po e tin alfa group and 4.48 points (95% 
CI, 3.15 to 5.81) in the placebo group (treatment 
Table 2. Primary, Secondary, and Other Adjudicated Outcomes.
Outcome
Dar be po e tin Alfa 
(N = 1136)
Placebo 
(N = 1142)
Hazard Ratio 
(95% CI)* P Value†
no. of patients (%)
Primary composite outcome
Death from any cause or first hospitalization for worsening 
heart failure
576 (50.7) 565 (49.5) 1.01 (0.90–1.13) 0.87
Death from any cause 474 (41.7) 458 (40.1) 1.04 (0.92–1.19) 0.51
First hospitalization for worsening heart failure 314 (27.6) 311 (27.2) 0.99 (0.85–1.16) 0.92
Secondary composite outcome
Death from cardiovascular causes or first hospitalization for 
worsening heart failure
513 (45.2) 506 (44.3) 1.01 (0.89–1.14) 0.92
Death from cardiovascular causes 388 (34.2) 376 (32.9) 1.04 (0.91–1.20) 0.56
Other adjudicated outcomes
Death from any cause or first nonfatal cardiovascular event‡ 607 (53.4) 589 (51.6) 1.04 (0.93–1.17) 0.49
Fatal or nonfatal myocardial infarction§ 64 (5.6) 74 (6.5) 0.84 (0.60–1.18) 0.32
Unstable angina 18 (1.6) 12 (1.1) 1.49 (0.72–3.09) 0.28
Fatal or nonfatal stroke¶ 42 (3.7) 31 (2.7) 1.33 (0.83–2.12) 0.23
Heart failure during ongoing hospitalization 25 (2.2) 22 (1.9) 1.08 (0.61–1.93) 0.78
Deep venous thrombosis 10 (0.9) 10 (0.9) 1.01 (0.42–2.43) 0.98
Fatal or nonfatal pulmonary embolism‖ 6 (0.5) 2 (0.2) 3.20 (0.64–15.90) 0.13
Resuscitation after cardiac arrest 12 (1.1) 15 (1.3) 0.77 (0.36–1.65) 0.50
* Hazard ratios and 95% confidence intervals were calculated with the use of stratified Cox models.
† P values were calculated by means of a stratified log-rank test and have not been adjusted for multiple comparisons.
‡ Cardiovascular events included in this category were myocardial infarction, unstable angina, stroke, heart failure during ongoing hospitaliza-
tion, hospitalization for worsening heart failure, deep venous thrombosis, pulmonary embolism, and resuscitation after cardiac arrest.
§ Myocardial infarctions were fatal in 19 patients in the dar be po e tin alfa group and 23 patients in the placebo group.
¶ A total of 15 patients in each study group had a fatal stroke.
‖ Pulmonary embolism was fatal only in 1 patient in the placebo group.
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difference, 2.20 points; 95% CI, 0.65 to 3.75; 
P = 0.005). The proportions of patients with an 
improvement in the Overall Summary Score of 
5 points or more at 6 months were 53% in the 
dar be po e tin alfa group and 48% in the placebo 
group (P = 0.06). The increases from baseline to 
6 months in the Symptom Frequency Score were 
6.20 points (95% CI, 4.71 to 7.69) in the dar be po­
e tin alfa group and 3.91 points (95% CI, 2.42 to 
5.40) in the placebo group (P = 0.01).
Adverse Events
In the dar be po e tin alfa group, 221 of 1133 patients 
(19.5%) had an adverse event leading to study­
drug discontinuation, as compared with 229 of 
1140 (20.1%) in the placebo group (P = 0.73). The 
most frequent serious adverse events, and those 
of particular interest, are summarized in Table 3 
and in more detail in Table S5 in the Supplemen­
tary Appendix. Embolic and thrombotic adverse 
events were reported in 153 patients (13.5%) in the 
dar be po e tin alfa group and 114 (10.0%) in the 
placebo group (P = 0.01) (Table 3, and Table S6 in 
the Supplementary Appendix). With respect to 
serious adverse events, septic shock was reported 
significantly more frequently in the dar be po e tin 
alfa group than in the placebo group, although 
there was no excess of other serious adverse events 
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Figure 2. Kaplan–Meier Estimates of the Probability of the Primary and Secondary Outcomes.
Shown are the primary composite outcome of death from any cause or first hospitalization for worsening heart failure (Panel A) and sec-
ondary outcomes of death from any cause (Panel B), death from cardiovascular causes (Panel C), and death from cardiovascular causes 
or first hospitalization for heart failure (Panel D). P values have not been adjusted for multiple comparisons.
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related to infection in the dar be po e tin alfa group 
(Table S7 in the Supplementary Appendix). A his­
tory of cancer at baseline was reported by 93 pa­
tients in the dar be po e tin alfa group and 78 in the 
placebo group. Of these patients, 44 in the dar­
be po e tin alfa group and 36 in the placebo group 
died; the deaths were attributed to cancer in 4 and 
6 of the patients, respectively, with no significant 
between­group differences. There was no signifi­
cant between­group difference in systolic blood 
pressure during the study, but the diastolic blood 
pressure was 1 mm Hg higher (median AUC) in 
the dar be po e tin alfa group than in the placebo 
group (P = 0.03).
Table 3. Adverse Events of Interest.*
Adverse Event
Dar be po e tin Alfa 
(N = 1133)
Placebo 
(N = 1140)
Risk Difference  
(95% CI)† P Value‡
no. of patients (%) percentage points
Any event of interest 660 (58.3) 662 (58.1) 0.2 (−3.9 to 4.2) 0.93
Cardiac failure 438 (38.7) 459 (40.3) −1.6 (−5.6 to 2.4) 0.43
Ischemic heart disease 155 (13.7) 164 (14.4) −0.7 (−3.6 to 2.2) 0.63
Cerebrovascular disorder
Any 61 (5.4) 45 (3.9) 1.4 (−0.3 to 3.2) 0.10
Hemorrhagic 39 (3.4) 30 (2.6) 0.8 (−0.6 to 2.2) 0.26
Ischemic 51 (4.5) 32 (2.8) 1.7 (0.2 to 3.2) 0.03
Embolic and thrombotic events
Any 153 (13.5) 114 (10.0) 3.5 (0.9 to 6.1) 0.009
Arterial§ 87 (7.7) 73 (6.4) 1.3 (−0.8 to 3.4) 0.24
Venous¶ 29 (2.6) 20 (1.8) 0.8 (−0.4 to 2.0) 0.19
Vessel type unspecified and mixed arterial 
and venous‖
51 (4.5) 27 (2.4) 2.1 (0.6 to 3.6) 0.005
Hemodialysis-related vascular access thrombosis 1 (0.1) 0 0.1 (−0.1 to 0.3) 0.50
Hypertension 81 (7.1) 69 (6.1) 1.1 (−0.9 to 3.1) 0.29
Cancer 69 (6.1) 68 (6.0) 0.1 (−1.8 to 2.1) 0.90
Convulsions 4 (0.4) 5 (0.4) −0.1 (−0.6 to 0.4) 1.00
Hypersensitivity reactions 99 (8.7) 96 (8.4) 0.3 (−2.0 to 2.6) 0.79
Antibody-mediated pure red-cell aplasia 0 0 NA NA
* Adverse events of interest were identified with the use of the prespecified Standard MedDRA (Medical Dictionary for 
Regulatory Activities) Query (SMQ) search strategies, as specified in the statistical analysis plan. Patients could have 
more than one event in each overall category. Data are for patients who received at least one dose of a study drug. NA 
denotes not applicable.
† The risk difference for each event was calculated as the percentage of patients with the event in the dar be po e tin alfa group 
minus the percentage of patients with the event in the placebo group. The 95% Wald asymptotic confidence intervals 
for the risk difference were calculated.
‡ P values were calculated with the use of Pearson’s chi-square test, except for hemodialysis-related vascular access 
thrombosis and convulsions, for which Fisher’s exact test was used. P values have not been adjusted for multiple com-
parisons.
§ Included in the arterial-events category are the following preferred terms: acute myocardial infarction, amaurosis fugax, 
carotid-artery occlusion, cerebrovascular insufficiency, coronary arterial stent insertion, coronary-artery occlusion, ischemic 
stroke, lacunar infarction, myocardial infarction, percutaneous coronary intervention, peripheral arterial occlusive disease, 
peripheral-artery thrombosis, peripheral embolism, retinal-artery occlusion, and transient ischemic attack.
¶ Included in the venous-events category are the following preferred terms: deep-vein thrombosis, jugular-vein thrombosis, 
pulmonary embolism, retinal-vein occlusion, thrombophlebitis, superficial thrombophlebitis, and limb venous thrombosis.
‖ Included in the unspecified events are the following preferred terms: bone infarction, cerebral infarction, cerebral isch-
emia, cerebrovascular accident, coronary-artery thrombosis, embolism, hemorrhagic stroke, hemiparesis, hemiplegia, 
heparin-induced thrombocytopenia, intestinal infarction, intracardiac thrombus, shunt occlusion, splenic infarction, 
thrombosis, thrombosis in device, mesenteric-vessel thrombosis, and thrombosis prophylaxis.
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Discussion
We evaluated the effect of correcting anemia in pa­
tients with systolic heart failure by adding dar be­
po e tin alfa to contemporary therapy, with a target 
hemoglobin level of 13.0 g per deciliter. As com­
pared with placebo, dar be po e tin alfa treatment led 
to an early and sustained increase in the hemo­
globin level. Despite this improvement, the use of 
dar be po e tin alfa did not reduce the risk of the pri­
mary outcome of death or hospitalization for wors­
ening heart failure. None of the other adjudicated 
outcomes differed significantly between the two 
study groups. The lack of effect of dar be po e tin alfa 
was consistent across all prespecified subgroups.
From a safety perspective, more patients had 
fatal or nonfatal strokes in the dar be po e tin alfa 
group than in the placebo group. Although the 
difference was not significant, this observation is 
in keeping with the findings of the Trial to Re­
duce Cardiovascular Events with Aranesp Therapy 
(TREAT),16 a study of dar be po e tin alfa in patients 
with diabetes, chronic kidney disease, and ane­
mia. As has been noted in other populations,17,18 
there was a significant increase in investigator­
reported arterial and venous thromboembolic 
events in patients receiving dar be po e tin alfa.
Although the rate of clinical events was not 
reduced in the dar be po e tin alfa group, treatment 
of anemia did improve the Overall Summary and 
Symptom Frequency Scores on the KCCQ. How­
ever, the average between­group difference and 
the difference in the proportion of patients with 
a clinically meaningful improvement in these 
scores were of questionable importance.
Although we enrolled patients with mild­to­
moderate anemia, they were at high risk for events, 
and we accrued the number of primary outcome 
events that were needed to test our hypothesis. Our 
patients were iron­replete at baseline, had a high 
use of iron during the study (as dictated by the 
study protocol), and did not become iron­deficient 
during the study. The protocol­defined hemoglo­
bin target of 13.0 g per deciliter was attained in the 
dar be po e tin alfa group, and the median between­
group difference in the hemoglobin level was 1.5 g 
per deciliter (since there was a slight increase in 
hemoglobin level in the placebo group). Observa­
tional studies have shown that outcomes are worse 
in patients with heart failure who have a hemoglo­
bin level of less than 12.0 g per deciliter than in 
those with a hemoglobin level of 12.0 g per deci­
liter or more.2,23 Moreover, in these studies, a 
change of 1 g per deciliter was associated with a 
difference in all­cause mortality of approximately 
15 to 20 percentage points (and a similar differ­
ence in a composite of all­cause mortality or heart­
failure hospitalization).23 Consequently, our find­
ings suggest that the hemoglobin level, like other 
surrogates, is simply a marker of poor prognosis 
in heart failure rather than a therapeutic target.
A limitation of our study is that we excluded 
patients with severe anemia (hemoglobin level, 
<9.0 g per deciliter). Such patients might have a 
greater increase in hemoglobin values with dar­
be po e tin alfa (with greater separation from the 
findings in the placebo group). However, severe 
anemia is uncommon in patients with heart fail­
ure. Also, we tested one approach to elevating the 
hemoglobin level, and other strategies may have 
different effects.
In summary, we found that the correction of 
anemia with the use of dar be po e tin alfa did not 
reduce the rate of death or hospitalization among 
patients with systolic heart failure who were re­
ceiving contemporary treatment. Moreover, there 
was a significant increase in the risk of throm­
boembolic events among patients receiving dar­
be po e tin alfa. Our findings do not support the 
use of dar be po e tin alfa in patients with systolic 
heart failure and mild­to­moderate anemia.
Supported by Amgen.
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